✦ LIBER ✦

Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer

✍ Scribed by Rougier, Philippe; Riess, Hanno; Manges, Robert; Karasek, Petr; Humblet, Yves; Barone, Carlo; Santoro, Armando; Assadourian, Sylvie; Hatteville, Laurence; Philip, Philip A.

Book ID: 121958501
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 916 KB
Volume: 49
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2013.04.002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Intravenous aflibercept for treatment of

Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study

✍ Walter H Gotlieb; Frederic Amant; Suresh Advani; Chanchal Goswami; Hal Hirte; Di 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 196 KB

A double-blind, randomised, placebo-cont

A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer

✍ Gradishar, William J.; Kaklamani, Virginia; Sahoo, Tarini P.; Lokanatha, Dasappa 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 820 KB

Motesanib, or open-label bevacizumab, in

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

✍ Miguel Martin; Henri Roche; Tamas Pinter; John Crown; M John Kennedy; Louise Pro 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 230 KB

Treatment Rationale and Study Design for

Treatment Rationale and Study Design for a Randomized, Double-Blind, Placebo-Controlled Phase II Study Evaluating Onartuzumab (MetMAb) in Combination With Bevacizumab Plus mFOLFOX-6 in Patients With Previously Untreated Metastatic Colorectal Cancer

✍ Bendell, Johanna C.; Ervin, Thomas J.; Gallinson, David; Singh, Jaswinder; Walla 📂 Article 📅 2013 🏛 CIG Media Group, LP. 🌐 English ⚖ 608 KB

RIBBON-2: A Randomized, Double-Blind, Pl

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

✍ Datko, F.M.; Dickler, M.N. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 295 KB

A Phase 2b, Double-Blind, Randomized Stu

A Phase 2b, Double-Blind, Randomized Study Evaluating the Efficacy and Safety of Sorafenib (SOR) Compared With Placebo (PBO) When Administered in Combination With Chemotherapy (Modified FOLFOX6) for First-line Treatment (tx) of Patients (Pts) With Metastatic Colorectal Cancer (mCRC). The RESPECT Trial

✍ J. Tabernero; R. Garcia-Carbonero; C.H. Könne; P.J. O'Dwyer; A. Sobrero; E. Van 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 50 KB